Daewoong Pexuclu Praised in Europe... Academic Symposium Held Locally

'Pexuclue Night' Symposium Held to Introduce New Drug
Marketing Authorization Applications to Be Submitted in 30 Countries by 2025

Daewoong Pharmaceutical announced on the 24th that the clinical data of its new drug for gastroesophageal reflux disease (GERD), 'Pexuclu,' received high praise from gastroenterology experts attending the '2023 United European Gastroenterology Week (UEGW 2023)'.

Daewoong Pharmaceutical held an academic symposium titled "Pexuclu Night" at UEGW 2023, which took place on the 16th (local time) in Copenhagen, Denmark. The symposium featured key domestic and international opinion leaders as speakers, introducing the strengths and clinical data of Pexuclu. Photo from the symposium venue.
[Photo by Daewoong Pharmaceutical]

On the 16th (local time), Daewoong Pharmaceutical held an academic symposium called 'Pexuclu Night' at UEGW 2023 in Copenhagen, Denmark, featuring key domestic and international opinion leaders as speakers to introduce the strengths and clinical data of Pexuclu.

At Pexuclu Night, Professor Oh-Young Lee, Chair of the Korean Society of Gastrointestinal Endoscopy and a gastroenterologist at Hanyang University Hospital, served as the chairperson. The symposium covered topics including ▲the development background and overseas expansion plans of Pexuclu ▲GERD and its treatment, and the clinical data of Pexuclu.

Daewoong Pharmaceutical explained that the key domestic and international opinion leaders showed the greatest interest in the clinical data of Pexuclu. They also agreed that the treatment paradigm for GERD is expected to shift from the conventional proton pump inhibitors (PPIs) to potassium-competitive acid blockers (P-CABs), which act faster and more powerfully.

Professor Jan Tack from KU Leuven in Belgium personally introduced the major clinical data of Pexuclu, emphasizing, "The clinical data of Pexuclu demonstrate a profile at the highest new drug level within the P-CAB class." Known as a global authority on GERD, Professor Tack serves as the chairman of the Rome Foundation, which develops diagnostic and treatment guidelines for functional gastrointestinal disorders, and acts as a reviewer for SCI(E)-level international journals such as the Journal of Gastrointestinal Motility.

According to the clinical data, Pexuclu has proven efficacy in improving heartburn symptoms caused by nocturnal acid breakthrough (NAB), rapidly and stably suppresses gastric acid regardless of food intake, and exhibits a half-life of up to 9 hours. This is the longest duration of effect among GERD treatments.

During the subsequent Q&A session, overseas medical professionals expressed interest in the overseas expansion potential and comparative advantages of P-CABs, showing anticipation for future changes in GERD treatment trends. Professor Tack emphasized, "Based on guidelines, P-CABs can be applied both as initial treatment for GERD patients and for those with recurrent GERD, and the treatment paradigm will shift from existing PPI formulations to P-CAB formulations."

Daewoong Pharmaceutical plans to continuously promote the strengths of Pexuclu overseas and increase the number of countries submitting marketing authorization applications to 30 by 2025. Currently, Pexuclu has submitted marketing authorization applications in a total of 12 countries, with approvals obtained in four countries (Philippines, Ecuador, Chile, Mexico). Daewoong Pharmaceutical aims to increase the number of countries applying for marketing authorization to 20 within this year.

Lee Chang-jae, CEO of Daewoong Pharmaceutical, said, "Through the Pexuclu Night event held at UEGW 2023, major gastroenterology experts from various countries formed a consensus on the paradigm shift centered on Pexuclu, which is deeply meaningful. We will continue to promote the strengths and excellence of Pexuclu domestically and internationally, focus on securing additional indications and formulation development, and nurture it as the No.1 GERD treatment drug that surpasses the best-in-class new drugs within the class after achieving global sales of 1 trillion KRW by 2030."

Professor Jantak from the University of Leuven, Belgium, is explaining Pexuclu at the Pexuclu Night held during the 2023 United European Gastroenterology Week (UEGW 2023).
[Photo by Daewoong Pharmaceutical]

This content was produced with the assistance of AI translation services.